Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Tóm tắt
Từ khóa
Tài liệu tham khảo
2017, AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology, 67, 358
2015, Cancer incidence and mortality: sources, methods and major patters in GLOBOCAN 2012, Int J Cancer, 136, E359
2013, Thirty‐year outcomes of the national hepatitis B immunization program in Taiwan, JAMA, 310, 974, 10.1001/jama.2013.276701
1999, Cancer mortality in East and Southeast Asian migrants to New South Wales, Australia, 1975‐1995, Br J Cancer, 79, 1277, 10.1038/sj.bjc.6690205
2004, Primary liver cancer: worldwide incidence and trends, Gastroenterology, 127, S5, 10.1053/j.gastro.2004.09.011
2017, Early age hepatocellular carcinoma associated with hepatitis B infection in South America, Clin Gastroenterol Hepatol, 15, 1631, 10.1016/j.cgh.2017.05.015
2016, Testosterone regulation of cyclin E kinase: a key factor in determining gender differences in hepatocarcinogenesis, J Gastroenterol Hepatol, 31, 1210, 10.1111/jgh.13232
2016, International trends in liver cancer incidence, overall and by histologic subtype, 1978‐2007, Int J Cancer, 139, 1534, 10.1002/ijc.30211
2016, Future of hepatocellular carcinoma incidence in the United States forecast through 2030, J Clin Oncol, 34, 1787, 10.1200/JCO.2015.64.7412
2012, Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review, Clin Gastroenterol Hepatol, 10, 1342, 10.1016/j.cgh.2012.10.001
1994, The meaning of life expectancy: what is a clinically significant gain?, J Gen Intern Med, 9, 702, 10.1007/BF02599016
1992, How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations, CMAJ, 146, 473
1996, Cost‐effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child‐Pugh class A cirrhosis, Am J Med, 101, 422, 10.1016/S0002-9343(96)00197-0
2004, Cost‐effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C, Aliment Pharmacol Ther, 19, 1159, 10.1111/j.1365-2036.2004.01963.x
2013, Detection of hepatocellular carcinoma at advanced stages among patients in the HALT‐C trial: where did surveillance fail?, Am J Gastroenterol, 108, 425, 10.1038/ajg.2012.449
2015, A genomic and clinical prognostic index for hepatitis C‐related early‐stage cirrhosis that predicts clinical deterioration, Gut, 64, 1296, 10.1136/gutjnl-2014-307862
2016, Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition, Cancer Cell, 30, 879, 10.1016/j.ccell.2016.11.004
2017, Proliferating EpCAM‐positive ductal cells in the inflamed liver give rise to hepatocellular carcinoma, Cancer Res, 77, 6131, 10.1158/0008-5472.CAN-17-1800
2016, Circulating osteopontin and prediction of hepatocellular carcinoma development in a large European population, Cancer Prev Res (Phila), 9, 758, 10.1158/1940-6207.CAPR-15-0434
2014, Cell‐surface Vimentin: A mislocalized protein for isolating csVimentin+CD133−novel stem‐like hepatocellular carcinoma cells expressing EMT markers, Int J Cancer, 137, 491
2018, Analysis of genomes and transcriptomes of hepatocellular carcinomas identifies mutations and gene expression changes in the transforming growth factor‐β pathway, Gastroenterology, 154, 195, 10.1053/j.gastro.2017.09.007
2017, XLF‐mediated NHEJ activity in hepatocellular carcinoma therapy resistance, BMC Cancer, 17, 344, 10.1186/s12885-017-3345-y
2004, Pathogenesis of hepatitis B virus—related hepatocellular carcinoma: old and new paradigms, Gastroenterology, 127, S56, 10.1053/j.gastro.2004.09.016
2006, Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level, JAMA, 295, 65, 10.1001/jama.295.1.65
2002, Hepatitis B e antigen and the risk of hepatocellular carcinoma, N Engl J Med, 347, 168, 10.1056/NEJMoa013215
2004, Hepatocellular carcinoma in cirrhosis: incidence and risk factors, Gastroenterology, 127, S35
2000, Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma, Int J Cancer, 85, 498, 10.1002/(SICI)1097-0215(20000215)85:4<498::AID-IJC9>3.0.CO;2-F
2011, Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?, J Gastroenterol Hepatol, 26, 221, 10.1111/j.1440-1746.2010.06576.x
2013, Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma, Clin Gastroenterol Hepatol, 11, 1636, 10.1016/j.cgh.2013.04.043
2003, Incidence and cofactors of hepatitis C virus‐related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan, Am J Epidemiol, 157, 674, 10.1093/aje/kwg041
2008, Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography, J Clin Gastroenterol, 42, 839, 10.1097/MCG.0b013e318050074f
2003, The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?, Am J Gastroenterol, 98, 2535, 10.1111/j.1572-0241.2003.07678.x
1999, Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan, Ann Intern Med, 131, 174, 10.7326/0003-4819-131-3-199908030-00003
2017, Oral direct‐acting agent therapy for hepatitis C virus infection, Ann Intern Med, 166, 637, 10.7326/M16-2575
2016, Sustained virologic response to interferon‐free therapies ameliorates HCV‐induced portal hypertension, J Hepatol, 65, 692, 10.1016/j.jhep.2016.05.027
2017, HCV eradication induced by direct‐acting antiviral agents reduces the risk of hepatocellular carcinoma, J Hepatol
2016, Unexpected high rate of early tumor recurrence in patients with HCV‐related HCC undergoing interferon‐free therapy, J Hepatol, 65, 719, 10.1016/j.jhep.2016.04.008
2016, Lack of evidence of an effect of direct‐acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts, J Hepatol, 65, 734, 10.1016/j.jhep.2016.05.045
2017, Hepatocellular carcinoma risk following direct‐acting antiviral HCV therapy: a systematic review, meta‐analyses, and meta‐regression, J Hepatol., 67, 1204, 10.1016/j.jhep.2017.07.025
2017, Direct‐acting antivirals and recurrence of hepatocellular carcinoma, Liver Transpl, 23, 1099, 10.1002/lt.24822
2016, Global epidemiology of nonalcoholic fatty liver disease‐Meta‐analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431
2010, The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, Hepatology, 51, 1972, 10.1002/hep.23527
2012, Large‐scale long‐term follow‐up study of Japanese patients with non‐alcoholic Fatty liver disease for the onset of hepatocellular carcinoma, Am J Gastroenterol, 107, 253, 10.1038/ajg.2011.327
2015, Characteristics of hepatocellular carcinoma in cirrhotic and non‐cirrhotic non‐alcoholic fatty liver disease, World J Gastroenterol, 21, 1189, 10.3748/wjg.v21.i4.1189
2015, Hepatocellular carcinoma in the setting of non‐cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience, Dig Dis Sci, 60, 3142, 10.1007/s10620-015-3821-7
2013, Population‐attributable fractions of risk factors for hepatocellular carcinoma in the United States, Am J Gastroenterol, 108, 1314, 10.1038/ajg.2013.160
2017, Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Cancer Control., 24, 1073274817729245
2004, Alcohol and hepatocellular carcinoma, Gastroenterology, 127, S87
2003, Cancer risk in patients with hereditary hemochromatosis and in their first‐degree relatives, Gastroenterology, 125, 1733, 10.1053/j.gastro.2003.09.035
2017, Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta‐analysis, Clin Gastroenterol Hepatol, 15, 1207, 10.1016/j.cgh.2017.02.006
2015, Alpha‐1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end‐stage liver disease, World J Hepatol, 7, 1427, 10.4254/wjh.v7.i10.1427
2014, A review of 218 pediatric cases of hepatocellular carcinoma, J Pediatr Surg, 49, 166, 10.1016/j.jpedsurg.2013.09.050
2014, Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta‐analysis, PLoS Med, 11, e1001624, 10.1371/journal.pmed.1001624
2016, An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis, Hepatology, 65, 1196
2016, Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis, Aliment Pharmacol Ther, 45, 169
2017, Screening and surveillance of hepatocellular carcinoma: an introduction to Ultrasound Liver Imaging Reporting and Data System, Radiol Clin North Am, 55, 1197, 10.1016/j.rcl.2017.06.012
2008, MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies, Radiology, 247, 311, 10.1148/radiol.2472061331
2003, Test characteristics of α‐fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C, Ann Intern Med, 139, 46, 10.7326/0003-4819-139-1-200307010-00012
2016, Improved detection of hepatocellular carcinoma by using a longitudinal alpha‐fetoprotein screening algorithm, Clin Gastroenterol Hepatol, 14, 469, 10.1016/j.cgh.2015.07.049
2015, The updated model: an adjusted serum alpha‐fetoprotein–based algorithm for hepatocellular carcinoma detection with hepatitis C virus‐related cirrhosis, Gastroenterology, 149, 1986, 10.1053/j.gastro.2015.10.004
2007, The utility of Lens culinaris agglutinin‐reactive alpha‐fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population, Cin Gastroenterol Hepatol, 5, 394, 10.1016/j.cgh.2006.12.005
1979, Studies on a subcellular system for vitamin K‐dependent carboxylation, Thromb Haemost, 41, 529, 10.1055/s-0038-1646805
1984, Des‐γ‐carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma, N Engl J Med, 310, 1427, 10.1056/NEJM198405313102204
1990, Plasma des‐gamma‐carboxyprothrombin in the early stage of hepatocellular carcinoma, Hepatology, 11, 481, 10.1002/hep.1840110321
2009, Alpha‐fetoprotein, des‐gamma carboxyprothrombin, and lectin‐bound alpha‐fetoprotein in early hepatocellular carcinoma, Gastroenterology, 137, 110, 10.1053/j.gastro.2009.04.005
2013, The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers, Cancer Epidemiol Biomarkers Prev, 23, 144
2017, Imaging‐based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results, Eur Radiol, 27, 4472, 10.1007/s00330-017-4844-6
2008, Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design, J Natl Cancer Inst, 100, 1432, 10.1093/jnci/djn326
2017, MRI with liver‐specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma, JAMA Oncol, 3, 456, 10.1001/jamaoncol.2016.3147
2015, Diagnostic per‐patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid–enhanced MRI for hepatocellular carcinoma surveillance, Am J Roentgenol, 204, 527, 10.2214/AJR.14.12986
2017, Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion‐weighted and T1‐weighted imaging at the delayed phase post gadoxetic acid, Abdom Radiol (NY), 42, 179, 10.1007/s00261-016-0841-5
2016, Diffusion‐weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening, J Med Imaging Radiat Oncol, 61, 34
2018, Evidence supporting LI‐RADS major features for CT‐ and MR imaging–based diagnosis of hepatocellular carcinoma: a systematic review, Radiology, 286, 29, 10.1148/radiol.2017170554
2017, Diagnostic efficacy of the Liver Imaging‐Reporting and Data System (LI‐RADS) with CT imaging in categorising small nodules (10‐20 mm) detected in the cirrhotic liver at screening ultrasound, Clin Radiol, 72, 901
1988, Isolation and characterization of rotavirus from feral pigeon in mammalian cell cultures, Epidemiol Infect, 100, 481, 10.1017/S0950268800067212
2016, Liver Imaging Reporting and Data System v2014 with gadoxetate disodium–enhanced magnetic resonance imaging, Invest Radiol, 51, 483, 10.1097/RLI.0000000000000258
2018, Extracellular contrast agent‐enhanced MRI: 15‐min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease, Eur Radiol, 28, 1551, 10.1007/s00330-017-5119-y
2017, Accuracy of the diagnostic evaluation of hepatocellular carcinoma with LI‐RADS, Acta Radiol, 59, 140
2018, Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI‐RADS) in gadoxetate‐enhanced MRI, Eur Radiol, 28, 2038, 10.1007/s00330-017-5188-y
2016, Natural history of liver imaging reporting and data system category 4 nodules in MRI, Abdom Radiol (NY), 41, 1758, 10.1007/s00261-016-0762-3
2016, Imaging Outcomes of Liver Imaging Reporting and Data System Version 2014 category 2, 3, and 4 observations detected at CT and MR imaging, Radiology, 281, 152173
2017, Liver imaging reporting and data system category 4 observations in MRI: risk factors predicting upgrade to category 5, J Magn Reson Imaging, 46, 783, 10.1002/jmri.25627
2018, Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta‐analysis, Hepatology, 67, 401, 10.1002/hep.29487
2017, Diagnostic value of contrast‐enhanced ultrasound in hepatocellular carcinoma: a meta‐analysis with evidence from 1998 to 2016, Oncotarget, 8, 75418, 10.18632/oncotarget.20049
1983, Morphologic studies of the liver cell dysplasia, Cancer, 51, 2197, 10.1002/1097-0142(19830615)51:12<2197::AID-CNCR2820511208>3.0.CO;2-5
2008, Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular Neoplasia, Hepatology, 49, 658
2013, Positive glypican‐3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy, J Gastroenterol, 49, 117
2012, Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma, Gut, 61, 1481, 10.1136/gutjnl-2011-301862
2010, The challenge of prognosis and staging for hepatocellular carcinoma, Oncologist, 15, 23
2012, EASL‐EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma, J Hepatol, 56, 908, 10.1016/j.jhep.2011.12.001
2005, Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort, Hepatology, 41, 707, 10.1002/hep.20636
2006, Prospective validation of the Barcelona Clinic Liver Cancer staging system, J Hepatol, 44, 723, 10.1016/j.jhep.2005.12.015
2009, Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method – Analysis of 2010 Taiwanese patients, Eur J Cancer, 45, 1630, 10.1016/j.ejca.2008.12.025
2014, Development of Hong Kong Liver Cancer Staging System with treatment stratification for patients with hepatocellular carcinoma, Gastroenterology, 146, 1691, 10.1053/j.gastro.2014.02.032
2017, Validation of the Hong Kong Liver Cancer Staging System in determining prognosis of the North American patients following intra‐arterial therapy, Clin Gastroenterol Hepatol, 15, 746, 10.1016/j.cgh.2016.10.036
1994, Users' guides to the medical literature. V. How to use an article about prognosis. Evidence‐Based Medicine Working Group, JAMA, 272, 234, 10.1001/jama.1994.03520030076032
2008, Patient‐physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer, Cancer, 113, 2205, 10.1002/cncr.23856
1996, Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 334, 693, 10.1056/NEJM199603143341104
2005, Portal vein embolization with N‐butyl cyanoacrylate before partial hepatectomy in patients with hepatocellular carcinoma and underlying cirrhosis or advanced fibrosis, J Vasc Interv Radiol, 16, 1667, 10.1097/01.RVI.0000182183.28547.DC
2009, Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: perioperative outcome and survival, Surgery, 145, 399, 10.1016/j.surg.2008.10.009
2011, Preoperative portal vein embolization (PVE) for patients with hepatocellular carcinoma can improve resectability and may improve disease‐free survival, J Surg Oncol, 104, 641, 10.1002/jso.21928
2016, The utility of unilobar technetium‐99m macroaggregated albumin to predict pulmonary toxicity in bilobar hepatocellular carcinoma prior to yttrium‐90 radioembolization, J Vasc Interv Radiol, 27, 1453, 10.1016/j.jvir.2016.06.004
2014, Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma, Clin Radiol, 69, 172, 10.1016/j.crad.2013.09.009
2013, Long‐term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single‐center experience, Ann Surg, 257, 506, 10.1097/SLA.0b013e31827b947a
2014, Laparoscopic vs. open liver resection for hepatocellular carcinoma of cirrhotic liver: a case‐control study, World J Surg, 38, 2919, 10.1007/s00268-014-2659-z
2015, Long‐term and perioperative outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with propensity score matching: a multi‐institutional Japanese study, J Hepatobiliary Pancreat Sci, 22, 721, 10.1002/jhbp.276
2016, Laparoscopic liver resection for hepatocellular carcinoma in cirrhotic patients: 10‐year single‐center experience, Surg Endosc, 30, 638, 10.1007/s00464-015-4253-3
2017, Pure laparoscopic versus open right hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a propensity score matched analysis, Ann Surg, 265, 856, 10.1097/SLA.0000000000002072
2017, Personalized treatment of patients with very early hepatocellular carcinoma, J Hepatol, 66, 412, 10.1016/j.jhep.2016.09.012
2002, Long‐term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function, Ann Surg, 235, 373, 10.1097/00000658-200203000-00009
2015, Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis, Ann Surg, 261, 947, 10.1097/SLA.0000000000000710
2015, Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double‐blind, placebo‐controlled trial, Lancet Oncol, 16, 1344, 10.1016/S1470-2045(15)00198-9
2001, A model to predict survival in patients with end‐stage liver disease, Hepatology, 33, 464, 10.1053/jhep.2001.22172
2004, Improving liver allocation: MELD and PELD, Am J Transplant, 114
2004, Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy, Gastroenterology., 127, S261
2013, New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma, Radiology, 266, 376, 10.1148/radiol.12121698
2010, Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system, Am J Transplant, 10, 1643
2015, Downstaging of hepatocellular cancer before liver transplant: long‐term outcome compared to tumors within Milan criteria, Hepatology, 61, 1968, 10.1002/hep.27752
2008, Liver transplantation for hepatocellular carcinoma: results of down‐staging in patients initially outside the Milan selection criteria, Am J Transplant, 8, 2547, 10.1111/j.1600-6143.2008.02409.x
2012, Recommendations for liver transplantation for hepatocellular carcinoma: an International Consensus Conference report, Lancet Oncol, 13, e11, 10.1016/S1470-2045(11)70175-9
2007, Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long‐term survival, Ann Surg, 245, 51, 10.1097/01.sla.0000225255.01668.65
2018, Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: an intention‐to‐treat analysis, Hepatology, 67, 204, 10.1002/hep.29468
2017, Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story, Ann Surg, 265, 557, 10.1097/SLA.0000000000001966
2007, Recurrence of hepatocellular carcinoma after liver transplantation, Transplant Proc., 39, 2308, 10.1016/j.transproceed.2007.06.042
2017, Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant, JAMA Oncol, 3, 493, 10.1001/jamaoncol.2016.5116
2010, Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta‐analysis, J Hepatol, 52, 380, 10.1016/j.jhep.2009.12.004
2009, Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies, Hepatology, 49, 453, 10.1002/hep.22648
2010, Microwave coagulation therapy for hepatic tumors: review of the literature and critical analysis, Surg Oncol, 19, e22, 10.1016/j.suronc.2009.02.001
2015, Image‐guided ablation of malignant liver tumors: recommendations for clinical validation of novel thermal and non‐thermal technologies: a Western perspective, Liver Cancer, 4, 208, 10.1159/000367747
2012, Local‐regional treatment of hepatocellular carcinoma, Radiology, 262, 43, 10.1148/radiol.11110144
2013, Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta‐analysis of randomized‐controlled trials, Eur J Gastroenterol Hepatol, 25, 187, 10.1097/MEG.0b013e32835a0a07
2008, Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial, JAMA, 299, 1669, 10.1001/jama.299.14.1669
2016, Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta‐analysis, Clin Res Hepatol Gastroenterol, 40, 309, 10.1016/j.clinre.2015.07.008
2004, Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma, Hepatology, 40, 1352, 10.1002/hep.20465
2009, Radiofrequency ablation of hepatocellular carcinoma: long‐term results and prognostic factors in 235 Western patients with cirrhosis, Hepatology, 50, 1475, 10.1002/hep.23181
2015, Local recurrence after radiofrequency ablation of hepatocellular carcinoma: treatment choice and outcome, J Gastrointest Surg, 19, 1466, 10.1007/s11605-015-2850-z
2013, Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma, PLoS One, 8, e79854, 10.1371/journal.pone.0079854
2017, Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention‐to‐treat analysis, J Hepatol, 67, 92, 10.1016/j.jhep.2017.02.022
2016, Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma, J Clin Oncol, 34, 452, 10.1200/JCO.2015.61.4925
2016, Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis, Int J Radiat Oncol Biol Phys, 95, 477, 10.1016/j.ijrobp.2016.02.027
2002, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, Lancet, 359, 1734, 10.1016/S0140-6736(02)08649-X
2002, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology, 35, 1164, 10.1053/jhep.2002.33156
2014, Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial, Hepatology, 60, 1697, 10.1002/hep.27290
2012, Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design, J Hepatol, 56, 1330, 10.1016/j.jhep.2012.01.008
2010, Prospective randomized study of doxorubicin‐eluting‐bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V Study, Cardiovasc Intervent Radiol, 33, 41, 10.1007/s00270-009-9711-7
2016, Drug‐eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta‐analysis, Dig Liver Dis, 48, 571, 10.1016/j.dld.2016.02.005
2016, Sorafenib or placebo plus TACE with doxorubicin‐eluting beads for intermediate stage HCC: the SPACE trial, J Hepatol, 64, 1090, 10.1016/j.jhep.2016.01.012
2012, Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma, J Gastroenterol Hepatol, 27, 1051, 10.1111/j.1440-1746.2011.06963.x
2013, The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma, Hepatology, 57, 2261, 10.1002/hep.26256
2016, TACE Treatment in patients with sorafenib‐treated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON, Radiology, 279, 630, 10.1148/radiol.2015150667
2012, Radioembolization for hepatocellular carcinoma, J Hepatol, 56, 464, 10.1016/j.jhep.2011.07.012
2011, Radioembolization results in longer time‐to‐progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma, Gastroenterology, 140, 497, 10.1053/j.gastro.2010.10.049
2013, Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma, Cardiovasc Intervent Radiol, 36, 714, 10.1007/s00270-012-0481-2
2015, Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma, Liver Int, 35, 1715, 10.1111/liv.12750
2016, Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma, Gastroenterology, 151, 1155, 10.1053/j.gastro.2016.08.029
2016, Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: a systematic review and meta‐analysis, World J Hepatol, 8, 770, 10.4254/wjh.v8.i18.770
2009, Efficacy and safety of sorafenib in patients in the Asia‐Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double‐blind, placebo‐controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7
2014, Yttrium‐90 radioembolization vs sorafenib for intermediate‐locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis, Liver Int, 35, 1036
2017, Efficacy and safety of selective internal radiotherapy with yttrium‐90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open‐label randomised controlled phase 3 trial, Lancet Oncol, 18, 1624, 10.1016/S1470-2045(17)30683-6
2018, SIRveNIB: selective internal radiation therapy versus sorafenib in Asia‐Pacific patients with hepatocellular carcinoma, J Clin Oncol
2018, Lenvatinib versus sorafenib in first‐line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non‐inferiority trial, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1
2017, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double‐blind, placebo‐controlled, phase 3 trial, Lancet, 389, 56, 10.1016/S0140-6736(16)32453-9
2015, Immune checkpoint blockade in cancer therapy, J Clin Oncol, 33, 1974, 10.1200/JCO.2014.59.4358
2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open‐label, non‐comparative, phase 1/2 dose escalation and expansion trial, Lancet, 389, 2492, 10.1016/S0140-6736(17)31046-2
2014, Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor, Recent Results Cancer Res, 201, 207, 10.1007/978-3-642-54490-3_12
2017, Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo‐controlled randomized discontinuation study, Ann Oncol, 28, 528, 10.1093/annonc/mdw651
2018, Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial, J Clin Oncol, 36, 207
2017, Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma, J Hepatol, 66, 545, 10.1016/j.jhep.2016.10.029
2013, Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome, Ann Surg Oncol, 21, 1287